152results about How to "Reduce body fat" patented technology

The present invention relates to a composition for treating obesity-related diseases comprising an insulinotropic peptide conjugate, more particularly, to a composition for treating obesity-related diseases comprising a conjugate prepared by covalently linking the insulinotropic peptide with a carrier substance via a non-peptidyl linker, and a method for treating obesity-related diseases by using the same. In particular, the composition for treating obesity-related diseases according to the present invention remarkably improves the efficacy of suppressing food intake and its duration to reduce body weight and body fat, thereby being useful for the treatment of obesity-related diseases.

The invention discloses a meal replacement protein powder solid beverage for managing the body weight and belongs to the field of nutrient foods. The solid beverage comprises the following components of soybean isolated protein, dried skim milk, whey protein concentrate, resistant dextrin, inulin, L-carnitine, a white kidney bean extract, a guarana extract, soy dietary fiber powder, pea fiber, oat fiber, erythritol, stevioside, phospholipid, Arabic gum, xanthan gum, pectin, alkalized cocoa powder, xylooligosaccharide and edible essence. By comprehensively considering the difference of nutrient components required by a human body at daytime and nighttime, the solid beverage disclosed by the invention is reasonable in formula matching and balanced in nutrition, and is the meal replacement solid beverage for supplementing the nutrients of the human body and controlling the body weight; the production process is simple and the drying is avoided; the damage to plant extracts and other components is prevented, so that the effects of nutrient components are guaranteed; besides, no sugar is added in the formula of the meal replacement protein powder solid beverage, so that the meal replacement protein powder solid beverage is suitable for being eaten by people with diabetes.

The present invention relates to a novel botanical compound as provided in structural formula I optionally along with excipients for improving body composition and the factors related to the pre-diabetic and diabetic conditions. It also relates to a process of manufacture of the novel botanical compound for improving body composition and factors related to the pre-diabetic and diabetic conditions. The present invention also relates to the use of the novel botanical compound for improving body composition, reducing body fat, increasing muscle mass, enhancing strength and improving impaired glucose metabolism. The present invention also relates to the use of the novel botanical compound for the improvement of factors related to the pre-diabetic and diabetic conditions.

The invention discloses lactobacillus reuteri capable of intervening in metabolic syndrome and application, and belongs to the technical field of microorganisms. The lactobacillus reuteri CCFM1145 screened by the invention can significantly improve the increase of serum total cholesterol content of metabolic syndrome mice caused by high fat diet. The weight rise of metabolic syndrome individuals is relieved, and the daily diet intake and the energy efficiency are remarkably reduced. Fasting blood glucose and insulin resistance index levels of metabolic syndrome individuals are significantly improved. The rise of Romboutsia in the intestinal tract caused by high fat diet is obviously relieved. The levels of anti-oxidative stress CAT and SOD in the liver are remarkably improved, serum lipopolysaccharide endotoxin is inhibited, and a colon barrier structure is maintained. The lactobacillus reuteri CCFM1145 disclosed by the invention can be used for preparing pharmaceutical compositions and fermented foods for relieving diseases such as metabolic syndrome, non-alcoholic fatty liver disease and diabetes mellitus and the like, and has a very wide application prospect.

The invention relates to pudding powder for losing weight and a preparation method of the pudding powder. The pudding powder is prepared by the following components in percentage by weight: 20-50% of polydextrose, 20-50% of crystalline fructose, 3-12% of isomaltulose, 1-6% of konjac glucomannan, 2-6% of carrageenan, 1-5% of xanthan gum, 1-5% of L-carnitine or salt of the L-carnitine, and 1-5% of guarana extract. The pudding powder provided by the invention has a weight-losing effect, and is good in mouthfeel, and easy to be accepted by a great number of consumers.

Pentacyclic triterpene compounds are provided herein. Also provided are pharmaceutical formulations containing a therapeutically effective amount of one or more of the compounds, or pharmaceutically acceptable salts or prodrugs thereof, in combination with one or more pharmaceutically acceptable excipients. The pharmaceutical formulations can be administered to a pre-obese, obese, or morbidly obese patient to induce weight loss, reduce body fat, reduce food intake, improve glucose homeostasis, prevent obesity, or a combination thereof. The compounds can also be co-administered with leptin or a leptin analog.

The invention discloses a red date diglyceride micro milk beverage, consisting of the components by weight percentage: 20-40 percent of 1,3-diglyceride micro-emulsion, 1-3 percent of jujube juice, 3-5 percent of defatted milk powder, 8-12 percent of sugar, 0.2-0.3 percent of citric acid, 0.45-0.6 percent of compound stabilizer and the balance of water. The invention also discloses a preparation method of the red date diglyceride micro milk beverage, comprising the following steps of: (1) preparing raw materials of beverage; (2) blending and mixing; (3) sequentially filtering, homogenizing at high pressure, degassing and filling the mixed solution; and (4) sequentially sterilizing and cooling the filled red date diglyceride micro milk beverage to obtain the finished red date diglyceride micro milk beverage. The beverage has the characteristics of abundant nutrients, maintenance of beauty and young, stomach and spleen enhancement and the like.

The invention provides an application of lactobacillus plantarum powder in regulating fat metabolism and intestinal flora of fat rats. The lactobacillus plantarum powder can reduce the in-vivo fat content, increased under induction of high-fat diet, of rats and reduce the body fat rate; the FFA content, increased under induction of high-fat diet, in serum of rats can be remarkably reduced; meanwhile, the TG content in the serum of obese rats can be reduced, and the HDL-C content is increased; the lipid metabolism function of the livers of the obese rats can be improved, and activation of a fatty acid synthesis pathway of the obese rats is inhibited; the condition of intestinal flora disorder of the obese rats can be improved, and the flora richness, flora diversity, flora structure and composition of the obese rats can be maintained; increase of relative abundance of firmicutes is inhibited; the relative abundance of bacteroides is improved; the relative abundance ratio of the firmicutes to the bacteroides in intestinal tracts of rats under the condition of high fat diet is reduced; and the similarity of intestinal flora of the obese rats and healthy rats is increased.

Disclosed is an edible oil grease composition containing high purity medium-chain diglyceride, which is prepared through mixing phosphatide, medium chain fatty acid, glycerin, fat hydrolytic enzyme and phosphatide hydrolytic enzyme by a weight ratio of 100:1-80:0-20:0.1-15:0.1-15, carrying out dephosphorization reaction and ester exchange reaction at 30-90 Degrees, proceeding distillation and purification, finally removing the phosphatide, triglyceride and free fatty acid in the product.

The invention discloses a bacterial strain as well as a composition and application, and relates to the technical field of strain separation and application. The Cristinia sp. provided by the invention can be applied to treatment or prevention of liver function impairment and liver function impairment related diseases, alimentary canal mucosal injury and alimentary canal mucosal injury related diseases, diabetes, obesity and obesity related diseases. The inventor verifies that the Cristinia sp. provided by the invention has no toxic or side effect on the kidney and can reduce the weight of the liver; the initial steatohepatitis focus can be treated; fat accumulation of liver cells can be slowed down; AST and ALT in serum can be reduced; and abdominal white fat inflammatory lesion can be reduced. The Cristinia sp. can also repair the digestive tract mucosa, recover the barrier function of the mucosa, and prevent and treat intestinal leakage, peptic ulcer and other diseases caused by barrier function impairment. The Cristinia sp. also has the effects of reducing fasting blood-glucose of a body, regulating insulin level and reducing body fat of mammals, and has the effects of preventing and treating diabetes and improving the metabolic function of obese patients.

The invention provides a weight reducing food and a making technology thereof. The weight reducing food is made from the following raw materials and components in parts by weight: 10-30 parts of conjugated linoleic acid microcapsule powder, 5-10 parts of chitosan, 5-15 parts of skimmed milk powder, 3-6 parts of matcha powder, 3-5 parts of inulin, 5-20 parts of resistant dextrin, 18-20 parts of whey protein powder and 15-20 parts of five-cereal powder. The weight reducing food obtained by hte making method disclosed by the invention has the efficacies of reducing body fat and reducing body weight. In the process of controlling the body weight, other nutrient substances are added, so that nutrition required by bodies can be sufficiently guaranteed. The purpose of reducing weight is achieved by controlling appetite, and a safe weight-reducing effect is achieved without the phenomenon that users become fat again after stopping eating the weight reducing food.

The invention relates to beverage, in particular to sugar-free l-carnitine beverage. 1000 parts by weight of sugar-free I-carnitine beverage consist of following components including, by weight, from 0.6 to 3 parts of l-carnitine, from 0.6 to 2.25 parts of DL-malic acid, from 0.05 to 0.25 part of sucralose, from 2.2 to 19.1 parts of erythritol, from 3.4 to 20 parts of maltodextrin and the balance water. The sugar-free l-carnitine beverage can be prepared by existing soft beverage processing technology. The sugar-free l-carnitine beverage is liquid beverage, and is convenient in drinking, easy to be absorbed and pure in taste, and is initiatively developed. Due to the sugar-free characteristic and the high-concentration purely natural l-carnitine and maltodextrin contents in the sugar-free l-carnitine beverage, the sugar-free l-carnitine beverage has effects of reducing body fat, losing weight, shaping perfect figure, improving male sperm motility and the like. The sugar-free l-carnitine beverage brings many benefits for increasing sports energy, strengthening exercise tolerance, resisting fatigue, promoting recovery after exercise and the like for athletes or common fitness-oriented people.

This document provides methods and materials related to managing weight, supporting appetite control, and controlling cravings associated with smoking reduction or cessation regimens and/or nicotine reduction or cessation regimens. For example, compositions comprising an agent to support acetylcholine and an agent to support one or more biogenic amines, and methods for using such compositions for craving and appetite control are provided. Methods and materials to reduce cravings associated with the reduction or cessation of the use of chemical substances (e.g., drugs of abuse, including opioids, cocaine, methamphetamine, cannabis, alcohol), and to reduce cravings associated with addictive and/or compulsive behaviors (e.g., gambling, sex, and repetitive behaviors) are also provided.

The invention discloses a preparation method of dandelion tea. The preparation method comprises the following steps of picking fresh dandelion leaves and eucommia leaves, performing thorough cleaning and performing spin-drying; performing shredding; performing microwave fixation ; performing blow-drying with hot blast; adding honey and performing twisting for 5-6 times; adding honeysuckle tea, dandelion roots, dried lotus leaves , green tea and Chinese wolfberry fruits and performing mixing; performing low-temperature freezing and drying; performing crushing; and performing vacuum packing . The dandelion tea prepared by the method disclosed by the invention is delicately fragrant in taste, slightly bitter, sweet in aftertaste and rich in nutrition.

The invention discloses lactobacillus reuteri CCFM1178 capable of intervening in metabolic syndrome, and application, and belongs to the technical field of microorganisms. The lactobacillus reuteri CCFM1178 screened by the invention can obviously eliminate increase of the serum total cholesterol content and the low-density lipoprotein cholesterol of a mouse with the metabolic syndrome caused by high fat diet, relieve the increase of the body weight of an individual with the metabolic syndrome, and reduce daily diet intake and energy conversion efficiency; the intestinal flora imbalance of the mouse due to high fat is eliminated; and the levels of proinflammatory factors IL-6 and TNF-[alpha] in the liver of the mouse with the metabolic syndrome are improved, and the level of an anti-inflammatory factor IL-10 is improved to prevent the metabolic syndrome, inhibit serum lipopolysaccharide endotoxin and maintain a colon barrier structure. The lactobacillus reuteri CCFM1178 disclosed by the invention can be used for preparing medicines or functional foods for relieving diseases such as the metabolic syndrome, the non-alcoholic fatty liver disease, the diabetes mellitus and the like, and has a very wide application prospect.

Pentacyclic triterpene weight loss agents are provided herein. Also provided are pharmaceutical formulations containing a therapeutically effective amount of one or more of the weight loss agents, or pharmaceutically acceptable salts or prodrugs thereof, in combination with one or more pharmaceutically acceptable excipients. The pharmaceutical formulations can be administered to a pre-obese, obese, or morbidly obese patient to induce weight loss, reduce body fat, reduce food intake, improve glucose homeostasis, prevent obesity, or a combination thereof. The weight loss agents can also be co-administered with leptin or a leptin analog.

The present invention relates to a new slimming and slenderizing medicine or health-care product. It is characterized by that its effective active component contains 2-10 weight portions of puerarin and 2-10 weight portions of icariine. It can effectively reduce body weight of human body and reduce body fat content.

The invention belongs to the preparation technical field of drug composite, which specifically relates to the preparation and application of drug composite for lowering blood pressure, blood sugar, blood ester, cholesterol and fat. The drug composite is produced by combining glycerin, olive oil, squalene and spirulina maxima. After clinical trials, the invention can significantly lower the blood pressure, blood leptin, the blood sugar, the blood ester, the cholesterol and body fat of rats. The drug composite can be produced to be oral tablet according to the production methods of conventional oral intake preparations. The invention can activate endogenous Leptin to combine with receptor, and can be used for lowering the level of the blood pressure, the cholesterol, triglycerides and the body fat, which has the characteristics of long-term effect, being easy to use, low cost and no toxicity and side effects. Simultaneously, the method can strengthen the assistant regulation of reproductive function.

The invention discloses bifidobacterium longum for relieving insulin resistance and application of the bifidobacterium longum, and belongs to the technical field of microorganisms. The bifidobacterium longum NSP008 disclosed by the invention can be used for inhibiting the increase of the body weight and the body fat of an insulin-resistant mouse on the premise of not influencing the food intake; the glucose tolerance of an insulin-resistant mouse is improved, and meanwhile, the blood sugar, serum insulin and an insulin resistance index of the mouse are reduced; the insulin-resistant mouse liver triglyceride and inflammation level can be adjusted, and liver tissue damage can be relieved; the intestinal flora structure is improved, and the growth of intestinal probiotics is promoted. The bifidobacterium longum NSP008 disclosed by the invention is used for preparing a pharmaceutical composition and fermented food for relieving insulin resistance, and has a very wide application prospect.

The invention discloses semi-fermented eucommia tea and a production process thereof. A technical scheme has the essential features: eucommia leaves are used as raw materials; and the process comprises the following steps in order: sunning leaves, making green, deactivating enzymes, rolling leaves, piling leaves, and drying and baking leaves. A semi-fermentation type production process is used for producing eucommia tea with thick aroma, the tea is mellow and tasty, all natural and beneficial components in the eucommia leaves are preserved, fat-reducing effects are excellent, and the process is convenient for market promotion.

The invention discloses feed for increasing the lean meat rate of pigs. The feed is prepared from, by weight, 45-55 parts of corn, 5-7 parts of sweet potatoes, 2-4 parts of table salt, 10-12 parts of peanut stalk, 5-7 parts of tartary buckwheat, 15-25 parts of buckwheat, 1-3 parts of semen cassia, 10-20 parts of dried apple pomace, 4-6 parts of shrimp shell meal, 5-7 parts of Chinese cabbage, 1-3 parts of alisma plantago-aquatica, 2-4 parts of rock flour, 4-6 parts of fish meal, 5-7 parts of lotus leaves and 1-3 parts of phagostimulant. According to the formula, in the process of fattening the pigs, the lean meat rate of the pigs can be increased remarkably, and the disease rate of the pigs is low.